从2026年4月1日起, Emcure和Roche合作伙伴将增加印度获得肾脏和移植药物的机会。 Emcure and Roche partner to boost access to kidney and transplant drugs in India starting April 1, 2026.

Emcure制药公司和Roche公司已同意从2026年4月1日起实施分配协议,以扩大印度获得肾病学和移植药物的机会。 Emcure Pharmaceuticals and Roche have agreed to a distribution deal effective April 1, 2026, to expand access to nephrology and transplant medicines in India. 埃姆库尔将分发罗氏的主要治疗方法,包括免疫抑制剂CellCept,Mircera和Neorecormon,用于慢性病和贫血治疗. Emcure will distribute Roche’s key treatments, including the immunosuppressant CellCept, Mircera, and Neorecormon, for chronic kidney disease and anemia management. 这一伙伴关系旨在通过Emcure的强大销售网络和印度不断增长的肾病部门的临床存在,改善病人获得关键治疗的机会。 The partnership aims to improve patient access to critical therapies through Emcure’s strong distribution network and clinical presence in India’s growing nephrology sector.